Literature DB >> 3318430

Controlled evaluation of nabumetone in the treatment of active adult rheumatoid arthritis. Nabumetone versus naproxen double-blind parallel study.

F B Vasey1, B F Germain, L R Espinoza, P Box, B I Bockow, J A Lipani, B J Mullen, A L Brodsky, R M Fleischmann, R A Fogari.   

Abstract

Nabumetone is a new nonsteroidal anti-inflammatory agent. Therapy with nabumetone 1,000 mg given at bedtime was compared with naproxen 250 mg given twice daily in a prospective double-blind study of patients with rheumatoid arthritis. Both drugs were found to be efficacious in a comparable fashion. Both drugs were well tolerated in terms of patient withdrawal rates, which were 5 and 8 percent, respectively. Gastrointestinal side effects were the most commonly encountered problem. Nabumetone holds promise as an important new therapeutic approach in arthritis.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3318430     DOI： 10.1016/0002-9343(87)90595-x

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  7 in total

1.  Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol.

Authors:  J D Bentkover; A M Baker; H Kaplan
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

2.  A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.

Authors:  M J Kendall; M C Chellingsworth; R Jubb; A R Thawley; N A Undre; D C Kill
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

4.  Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.

Authors:  R K Miehlke; S Schneider; F Sörgel; P Muth; F Henschke; K H Giersch; P Münzel
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  Efficacy and safety of nabumetone in 5,421 patients with osteoarthritis of the hip and/or knee joints. A subgroup evaluation of an outpatient study involving 18,047 patients.

Authors:  M Fedder; I Stroehmann
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  German drug monitoring studies with nabumetone.

Authors:  I Stroehmann; M Fedder; H Zeidler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 7.  Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases.

Authors:  H A Friedel; P A Todd
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.